Median NT-proBNP levels (pg/mL) by GFR and 60-day survival

Slides:

Advertisements

Similar presentations

Admission B-Type Natriuretic Peptide Levels and In-Hospital Mortality in Acute Decompensated Heart Failure Fonarow GC et al. J Am Coll Cardiol 2007; 49(19):

Advertisements

S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Selective heart rate reduction with ivabradine unloads the left ventricle in.

ACE inhibitors, ARBs and Statins in COPD: High- and Low-Risk Cohorts G. B. John Mancini, et al. J Am Coll Cardiol 2006;47:

Baseline Characteristics of 987 Individuals With Stable Coronary Heart Disease by Amino Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide.

The percentage of values for cardiac troponin (cTn)T associated with elevated values for a point-of-care assay with less sensitivity and precision: the.

NTproBNP for the Exclusion of Heart Failure Richard Blakey.

Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Prognostic Value of N-Terminal Pro–B-Type Natriuretic.

Date of download: 6/28/2016 Copyright © The American College of Cardiology. All rights reserved. From: Utility of B-type natriuretic peptide in the diagnosis.

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Local Renal Delivery of a Natriuretic Peptide: A.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: N-terminal pro brain natriuretic peptide on admission.

Clinical Outcomes with Newer Antihyperglycemic Agents

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, M.D., M.P.H, M.B.A. On behalf.

Estimated Glomerular Filtration Rate and Albuminuria Are Associated with Biomarkers of Cardiac Injury in a Population-Based Cohort Study: The Maastricht.

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy – Heart Failure Trial ATHENA-HF Trial Javed Butler, Marvin A. Konstam, G. Michael.

Clinical Outcomes with Newer Antihyperglycemic Agents

Intestinal Microbiota-Dependent Phosphatidylcholine Metabolites, Diastolic Dysfunction, and Adverse Clinical Outcomes in Chronic Systolic Heart Failure

The Association of Five-Year Changes in the Levels of N-Terminal Fragment of the Prohormone Brain-Type Natriuretic Peptide (NT-proBNP) with Subsequent.

REVEAL Registry PAH Risk Score Calculator

BNP in Heart Failure Azam Hadi MD 9/17/2018.

Plasma kidney injury molecule-1 in heart failure: renal mechanisms and clinical outcome Johanna E. Emmens, BSc, Jozine M. ter Maaten, MD, Yuya Matsue,

Sensitivity and specificity for various renal-related diagnoses (values are compared with an eGFR

Stephen W. Waldo et al. JACC 2008;51:

Atorvastatin 20 mg (n=25 lesions) Atorvastatin 5 mg (n=25 lesions)

Progression of CKD with ADMA levels above and below the median

End point Nesiritide Placebo p Peak SCr increase (mg/dL)

Creatinine clearance (mL/min) n All-cause mortality (%)

Clyde W. Yancy et al. JACC 2017;70:

The Utility of Biomarkers in Sorting Out the Complex Patient

Relationship between perioperative N-terminal pro-brain natriuretic peptide and maximum inotropic score in children after cardiac surgery Yanqin Cui,

Biomarker-Guided HF Therapy: Is It Cost-Effective?

The Heart Failure Team Heart Failure Care Map First 24 hours.

The Research Question The potential role of NT-proBNP in screening for heart failure and in predicting prognosis Richard Hobbs, Care Taylor, Andrea Roalfe,

Orly Vardeny et al. JCHF 2014;2:

G. Michael Felker et al. JCHF 2014;2:

Editorial Heart Failure Clinics

Overcoming Clinical Inertia

Incremental predictive value of CR after repetitive squatting exercise and FC from cardiopulmonary testing exercise results over clinical (red) and echocardiographic.

Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: a substudy of the OPTIMISE Trial M.A. Gillies, A.S.V.

Serum levels of angiopoietin-like protein 4 according to (A) cardiac dysfunction (ie, abnormal N-terminal pro-B-type natriuretic peptide level) and (B)

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Predictors of disease progression in patients with CKD

Ioannis Smyrnias et al. JACC 2019;73:

Volume 71, Issue 6, Pages (March 2007)

Risk factor Treatment GFR at baseline GFR at 5 years p Cadaveric donor

Risk assessment and treat-to-target approach for pulmonary arterial hypertension. Risk assessment and treat-to-target approach for pulmonary arterial hypertension.

Volume 71, Issue 6, Pages (March 2007)

Receiver operating characteristics curve of N-terminal pro-atrial natriuretic peptide plasma levels (dark line) and brain natriuretic peptide (dashed line)

Algorithm for the outpatient management of pulmonary embolism (PE)

Chronic effect of 28-day oral administration of vehicle (n = 6–10/group) or aprocitentan 1, 10, and 100 mg/kg per day (n = 6–9/group) on mean arterial.

Michael H. Chiu, MD, Msc, Nakul C. Sharma, MD, MPH CJC Open

Serum 25(OH)D levels stratified by the presence or absence of nephropathy. Serum 25(OH)D levels stratified by the presence or absence of nephropathy. The.

When we compared cardiac volumes (ED and ES) between those with high BNP levels (BNP >400 pg/mL) and low BNP (

Svend A. Mortensen et al. JCHF 2014;2:

Receiver-operating characteristics analyses for predicting AKI progression or AKI progression with death. Receiver-operating characteristics analyses for.

Volume 75, Issue 4, Pages (February 2009)

N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels for patients undergoing surgical aortic valve replacement (SAVR) (A), patients undergoing.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Results of classification and regression tree analysis in patients with pulmonary hypertension-sickle cell disease. Results of classification and regression.

Figure 1 Novel markers of increased stroke risk in AF

NT-proBNP calculator Age year Women Height cm Weight kg Hemoglobin

Associations of peripartum biomarker levels with e' at 1 month postpartum (PP2). Associations of peripartum biomarker levels with e' at 1 month postpartum.

N-terminal pro-B-type natriuretic peptide levels and early outcome after cardiac surgery: a prospective cohort study B.H. Cuthbertson, B.L. Croal, D.

Analysis of receiver operating characteristic of three models (model 1: cardiac troponin T (cTnT), N-terminal pro brain natriuretic peptide (NT-proBNP),

Spearman’s rank correlation between preoperative serum levels of BNP/NT-proBNP and expression of HIF-2 alpha and preoperative serum level of VEGF. There.

Changes in the plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) level from baseline to treatment titration and 3 months of therapy: full analysis.

Flow diagram of the recommended pharmacological management of heart failure adapted from the European Society of Cardiology guidelines Flow diagram.

Receiver operating curves assessing the prognostic accuracy of a) N-terminal pro-brain natriuretic peptide, b) pro-atrial natriuretic peptide, c) high-sensitivity.

Overall survival in all cases.

Standardised regression coefficients between blood variable levels and echocardiographic measurements. Standardised regression coefficients between blood.

Role of decreased baroreceptor sensitivity, and activation of RAAS and SNS in expansion of water and sodium retention as well as worsening HF. [Reprinted.

Presentation transcript:

Median NT-proBNP levels (pg/mL) by GFR and 60-day survival Admission GFR Dead by 60 d Alive at 60 d p <60 mL/min/1.73m2 5565 2528 0.001 >60 mL/min/1.73m2 1423 163 <0.001 NT-proBNP=N-terminal brain-type natriuretic peptide GFR=glomerular filtration rate Anwaruddin S et al. J Am Coll Cardiol 2005; available at http://www.sciencedirect.com.

Sensitivity and specificity for diagnosing HF, by NT-proBNP cut points and renal function Parameter GFR <60 mL/min/1.73 m2 GFR >60 mL/min/1.73 m2 (age >50 y) GFR >60 mL/min/1.73 m2 (age <50 y) Cut point (pg/mL) >1200 >900 >450 Sensitivity (%) 89 85 Specificity (%) 72 88 NT-proBNP=N-terminal brain-type natriuretic peptide GFR=glomerular filtration rate Anwaruddin S et al. J Am Coll Cardiol 2005; available at http://www.sciencedirect.com.